{
  "nct_id": "NCT06065748",
  "age": "Adults",
  "cancer_center_accrual_goal_upper": 0,
  "data_table4": "Interventional",
  "drug_list": {
    "drug": [
      {
        "drug_name": "Giredestrant"
      },
      {
        "drug_name": "Fulvestrant"
      },
      {
        "drug_name": "Abemaciclib"
      },
      {
        "drug_name": "Palbociclib"
      },
      {
        "drug_name": "Ribociclib"
      },
      {
        "drug_name": "LHRH Agonist"
      }
    ]
  },
  "long_title": "",
  "management_group_list": {
    "management_group": [
      {
        "is_primary": "Y",
        "management_group_name": "Group1"
      }
    ]
  },
  "oncology_group_list": {
    "oncology_group": [
      {
        "group_name": "Group1",
        "is_primary": "N"
      }
    ]
  },
  "phase": "3",
  "principal_investigator": "",
  "principal_investigator_institution": "Hoffmann-La Roche",
  "program_area_list": {
    "program_area": [
      {
        "is_primary": "Y",
        "program_area_name": "Program1"
      }
    ]
  },
  "protocol_id": null,
  "protocol_no": "",
  "protocol_target_accrual": 1050,
  "protocol_type": "",
  "prior_treatment_requirements": [
    "Locally advanced or metastatic adenocarcinoma of the breast, not amenable to treatment with curative intent",
    "Documented estrogen receptor-positive (ER+), HER2-negative (HER2-) tumor assessed locally on the most recent tumor biopsy (or an archived tumor sample if a recent tumor sample is not available for testing)",
    "Confirmed ESR1 mutation status (ESR1m versus ESR1nmd) in baseline circulating tumor DNA (ctDNA) through central laboratory testing",
    "Resistance to prior adjuvant endocrine therapy (ET), which is defined as having relapsed with prior standard adjuvant ET, on-treatment after â‰¥12 months or off-treatment within 12 months of completion. Prior use of neo/adjuvant CDK4/6i is allowed.",
    "No prior systemic anti-cancer therapy for advanced disease",
    "Measurable disease as defined per RECIST v.1.1 or non-measurable (including bone-only) disease",
    "Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-1",
    "For pre/perimenopausal women and for men- willing to undergo and maintain treatment with approved LHRH agonist therapy (as per local guidelines) for the duration of study treatment",
    "Exclude-Prior systemic therapy (e.g., prior chemotherapy, immunotherapy, or biologic therapy) for locally advanced unresectable or metastatic breast cancer",
    "Exclude-Prior treatment with another SERD (e.g., fulvestrant, oral SERDs) or novel ER-targeting agents",
    "Exclude-Advanced, symptomatic, visceral spread that is at risk of life-threatening complications in the short term",
    "Exclude-Active cardiac disease or history of cardiac dysfunction",
    "Exclude-Clinically significant history of liver disease"
  ],
  "short_title": "A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)",
  "site_list": {
    "site": []
  },
  "sponsor_list": {
    "sponsor": [
      {
        "is_principal_sponsor": "Y",
        "sponsor_name": "Hoffmann-La Roche",
        "sponsor_protocol_no": "CO44657",
        "sponsor_roles": "sponsor"
      }
    ]
  },
  "staff_list": {
    "protocol_staff": []
  },
  "status": "open to accrual",
  "summary": "This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib), in participants with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer who have developed resistance to adjuvant endocrine therapy.",
  "treatment_list": {
    "step": [
      {
        "step_code": "1",
        "step_type": "Registration",
        "step_internal_id": 1111,
        "arm": [
          {
            "arm_code": "Giredestrant + Investigator's Choice of CDK4/6i",
            "arm_internal_id": 1111,
            "arm_description": "Participants in the experimental arm will receive giredestrant plus the investigator's choice of CDK4/6 inhibitor (CDK4/6i): palbociclib, ribociclib, or abemaciclib.",
            "arm_suspended": "N",
            "dose_level": [
              {
                "level_code": "1",
                "level_description": "Giredestrant 30 milligrams (mg) orally (PO) once a day (QD) on Days 1-28 of each 28-day cycle until progressive disease (PD) or unacceptable toxicity.",
                "level_internal_id": 1,
                "level_suspended": "N"
              }
            ]
          },
          {
            "arm_code": "Fulvestrant + Investigator's Choice of CDK4/6i",
            "arm_internal_id": 2222,
            "arm_description": "Participants in the control arm will receive fulvestrant plus the investigator's choice of CDK4/6 inhibitor (CDK4/6i): palbociclib, ribociclib, or abemaciclib.",
            "arm_suspended": "N",
            "dose_level": [
              {
                "level_code": "1",
                "level_description": "Fulvestrant 500 mg intramuscularly (IM) on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent 28-day cycle until PD or unacceptable toxicity.",
                "level_internal_id": 1,
                "level_suspended": "N"
              }
            ]
          }
        ],
        "match": [
          {
            "and": [
              {
                "clinical": {
                  "oncotree_primary_diagnosis": "Invasive Breast Carcinoma",
                  "her2_status": "Negative",
                  "er_status": "Positive",
                  "disease_status": [
                    "Locally Advanced",
                    "Metastatic",
                    "Advanced"
                  ]
                }
              },
              {
                "genomic": {
                  "hugo_symbol": "ESR1",
                  "variant_category": "Mutation"
                }
              }
            ]
          }
        ]
      }
    ]
  }
}